XTL 바이오파마슈티컬 ADR(XTLB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.38 (-0.42%), 시가총액 $0.01B, 52주 최저~최고 $0.58 ~ $3.90.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ra
XTL 바이오파마슈티컬 ADR의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
XTL 바이오파마슈티컬 ADR의 현재 주가는 $2.38 (-0.42%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
XTL 바이오파마슈티컬 ADR의 시가총액은 약 $0.01B입니다.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate